CD34+, kit+, rhodamine123(low) phenotype identifies a marrow cell population highly enriched for human hematopoietic stem cells

Leukemia
M Z RatajczakA M Gewirtz

Abstract

We hypothesized that human hematopoietic cells displaying a CD34+, kit-, rhodamine123(low) phenotype would be highly enriched for cells with stem-like properties. To test this hypothesis, we employed fluorescence activated cell sorting (FACS) to isolate cells with this phenotype from normal light density marrow mononuclear cells (MNC). CD34+, kit+, rhodamine123(low) cells comprised from 0.05-0.01% of the total MNC population. They were small, had scant cytoplasm, and contained nuclei with dense, hyperchromatic chromatin and inconspicuous nucleoli. Additional immunophenotyping revealed that these cells were CD33-, CD38-, CD20-, and glycophorin A-. When plated in semisolid cultures containing optimal concentrations of IL-3, GM-CSF, KL, EPO, IL-6, and IL-1 these cells did not form colonies. However, when cultured over irradiated stromal cells, cobblestone areas were observed to form after 3 weeks, and harvested cells were able to initiate long-term cultures. To further demonstrate that these cells were indeed stem like, we also tested their ability to engraft and mature in immunocompromised (SCID) mice. Irradiated (400 cGy) SCID mice were transplanted with 2 x 10(3) candidate stem cells which were then injected with recombinant hu...Continue Reading

Citations

Dec 2, 2006·Veterinary Research Communications·S E SuterP S Henthorn
Jun 10, 2008·Current Opinion in Hematology·Mariusz Z Ratajczak
Jan 3, 2013·The Journal of Clinical Investigation·Piero AnversaAnnarosa Leri
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·R W StormsC Smith
Oct 6, 2005·Journal of Cellular and Molecular Medicine·Henry E YoungAsa C Black
Jan 13, 2004·Experimental Dermatology·Colin A B JahodaNicholas Hole
Dec 31, 2003·The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology·Henry E Young, Asa C Black
Apr 3, 2008·Cytometry. Part B, Clinical Cytometry·Sherry ShariatmadarAwtar Krishan
Jun 2, 2010·Cell Biology International·Michał PikułaPiotr Trzonkowski
Jul 21, 2004·Veterinary Immunology and Immunopathology·Steven E SuterPaula S Henthorn
Jun 29, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hitoshi MinamiguchiMakio Ogawa
May 26, 2009·São Paulo Medical Journal = Revista Paulista De Medicina·Jerusa Martins CarvalhoJosé Salvador Rodrigues de Oliveira
Nov 10, 2001·Annual Review of Biomedical Engineering·C M Roth, M L Yarmush
Sep 3, 2002·American Journal of Respiratory and Critical Care Medicine·Katsuyuki TomitaIan M Adcock
Dec 12, 2002·Oncogene·Richard A Van Etten
Dec 21, 2004·Oncogene·Georgina LangKathleen Weston
Feb 15, 2001·Oncogene·V I Sementchenko, D K Watson
Jul 5, 2018·Environmental Science and Pollution Research International·Jaishabanu AmeeramjaEkambaram Perumal
Dec 21, 2006·Journal of the National Cancer Institute·Igor ShuryakDavid J Brenner
Oct 26, 2016·Oncology Reports·Wojciech MarliczMariusz Z Ratajczak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.